nach oben

Advances in Therapy

Erschienen in:

30.01.2023 | Review

Τhe Endless Beauty of Metformin: Does It Also Protect from Skin Aging? A Narrative Review

verfasst von: Evanthia Gouveri, Nikolaos Papanas

Erschienen in: Advances in Therapy | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Metformin has shown multiple effects beyond its widely known antidiabetic effect. Impressively, it has already been proposed as an anti-aging factor. However, the potentially protective role of metformin in skin aging, the most common manifestation of aging, is not well examined. Existing evidence based on experimental studies suggests a potential anti-aging effect on skin. Proposed molecular skin anti-aging mechanisms of metformin include mainly reduction of nuclear factor kappa B (NF-κB) (p65) activity. Moreover, metformin appears to inhibit ultraviolet B (UVB)-induced secretion of pro-inflammatory cytokines. Nonetheless, data is still limited, and so more studies are needed. Importantly, we need more studies conducted in humans to further examine this interesting potential. Until then, whether oral administration of metformin or local use of the agent could be used to delay skin aging remains to be answered.

Top WMC, Kooy A, Stehouwer CDA. Metformin: a narrative review of its potential benefits for cardiovascular disease, cancer and dementia. Pharmaceuticals (Basel). 2022;15(3):312.CrossRefPubMed

Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des. 2009;15(27):3179–92.CrossRefPubMed

Papachristou S, Papanas N. Reduction of depression in diabetes: a new pleiotropic action of metformin? Diabetes Ther. 2021;12(4):965–8.CrossRefPubMedPubMedCentral

Papanas N, Maltezos E, Mikhailidis DP. Metformin and cancer: licence to heal? Expert Opin Investig Drugs. 2010;19(8):913–7.CrossRefPubMed

Malik F, Mehdi SF, Ali H, et al. Is metformin poised for a second career as an antimicrobial? Diabetes Metab Res Rev. 2018;34(4):e2975.CrossRefPubMed

Chen S, Gan D, Lin S, et al. Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms. Theranostics. 2022;12(6):2722–40.CrossRefPubMedPubMedCentral

Campbell JM, Bellman SM, Stephenson MD, Lisy K. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis. Ageing Res Rev. 2017;40:31–44.CrossRefPubMed

Wu L, Zhou B, Oshiro-Rapley N, et al. An ancient, unified mechanism for metformin growth inhibition in C. elegans and cancer. Cell. 2016;167(7):1705–1718.e13.

Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.CrossRefPubMed

10.

Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769–73.CrossRefPubMed

11.

Sorrenti V, Benedetti F, Buriani A, et al. Immunomodulatory and antiaging mechanisms of resveratrol, rapamycin, and metformin: focus on mTOR and AMPK signaling networks. Pharmaceuticals (Basel). 2022;15(8):912.CrossRefPubMed

12.

Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–6.CrossRefPubMedPubMedCentral

13.

Bridges HR, Sirviö VA, Agip AN, Hirst J. Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase. BMC Biol. 2016;14:65.CrossRefPubMedPubMedCentral

14.

Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–85.CrossRefPubMedPubMedCentral

15.

Cheng SC, Quintin J, Cramer RA, et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345(6204):1250684.CrossRefPubMedPubMedCentral

16.

Schuiveling M, Vazirpanah N, Radstake TRDJ, Zimmermann M, Broen JCA. Metformin, a new era for an old drug in the treatment of immune mediated disease? Curr Drug Targets. 2018;19(8):945–59.CrossRefPubMed

17.

Choi YJ. Shedding light on the effects of calorie restriction and its mimetics on skin biology. Nutrients. 2020;12(5):1529.CrossRefPubMedPubMedCentral

18.

Chen Q, Zhang H, Yang Y, et al. Metformin attenuates UVA-induced skin photoaging by suppressing mitophagy and the PI3K/AKT/mTOR pathway. Int J Mol Sci. 2022;23(13):6960.CrossRefPubMedPubMedCentral

19.

Soydas T, Yaprak Sarac E, Cinar S, et al. The protective effects of metformin in an in vitro model of aging 3T3 fibroblast under the high glucose conditions. J Physiol Biochem. 2018;74(2):273–81.CrossRefPubMed

20.

Soydas T, Sayitoglu M, Sarac EY, et al. Metformin reverses the effects of high glucose on human dermal fibroblasts of aged skin via downregulating RELA/p65 expression. J Physiol Biochem. 2021;77(3):443–50.CrossRefPubMed

21.

Wei J, Qi H, Liu K, Zhao C, Bian Y, Li G. Effects of metformin on life span, cognitive ability, and inflammatory response in a short-lived fish. J Gerontol A Biol Sci Med Sci. 2020;75(11):2042–50.CrossRefPubMed

22.

Fernández ÁF, Sebti S, Wei Y, et al. Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice. Nature. 2018;558:136–40.CrossRefPubMedPubMedCentral

23.

Chai M, Jiang M, Vergnes L, et al. Stimulation of hair growth by small molecules that activate autophagy. Cell Rep. 2019;27(12):3413–3421.e3.CrossRefPubMed

24.

Sun C, Hu SH, Dong BQ, Jiang S, Miao F, Lei TC. Metformin promotes the hair-inductive activity of three-dimensional aggregates of epidermal and dermal cells self-assembled in vitro. Skin Pharmacol Physiol. 2022;35:137–47.CrossRefPubMed

25.

Araoye EF, Thomas JAL, Aguh CU. Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Rep. 2020;6:106–8.CrossRefPubMedPubMedCentral

26.

Cavinato M, Jansen-Durr P. Molecular mechanisms of UVB-induced senescence of dermal fibroblasts and its relevance for photoaging of the human skin. Exp Gerontol. 2017;94:78–82.CrossRefPubMed

27.

Nayeri Rad A, Shams G, Safdarian M, Khorsandi L, Grillari J, Sharif MB. Metformin loaded cholesterol-lysine conjugate nanoparticles: a novel approach for protecting HDFs against UVB-induced senescence. Int J Pharm. 2020;586: 119603.CrossRefPubMed

28.

Kremslehner C, Miller A, Nica R, et al. Imaging of metabolic activity adaptations to UV stress, drugs and differentiation at cellular resolution in skin and skin equivalents—implications for oxidative UV damage. Redox Biol. 2020;37:101583.CrossRefPubMedPubMedCentral

29.

Ribeiro FM, Ratti BA, Dos Santos RF, et al. Metformin effect on driving cell survival pathway through inhibition of UVB-induced ROS formation in human keratinocytes. Mech Ageing Dev. 2020;192:111387.CrossRefPubMed

30.

Xiao T, Chen Y, Song C, et al. Possible treatment for UVB-induced skin injury: anti-inflammatory and cytoprotective role of metformin in UVB-irradiated keratinocytes. J Dermatol Sci. 2021;102(1):25–35.CrossRefPubMed

31.

Karthikeyan R, Kanimozhi G, Prasad NR, Agilan B, Ganesan M, Srithar G. Alpha pinene modulates UVA-induced oxidative stress, DNA damage and apoptosis in human skin epidermal keratinocytes. Life Sci. 2018;212:150–8.CrossRefPubMed

32.

Spampinato SF, Caruso GI, De Pasquale R, Sortino MA, Merlo S. The treatment of impaired wound healing in diabetes: looking among old drugs. Pharmaceuticals (Basel). 2020;13:60.CrossRefPubMed

33.

Zhao P, Sui BD, Liu N, et al. Anti-aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application. Aging Cell. 2017;16(5):1083–93.CrossRefPubMedPubMedCentral

34.

Pernicova I, Korbonits M. Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–56.CrossRefPubMed

35.

Amin S, Lux A, O’Callaghan F. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. Br J Clin Pharmacol. 2019;85(1):37–46.CrossRefPubMed

36.

Qing L, Fu J, Wu P, Zhou Z, Yu F, Tang J. Metformin induces the M2 macrophage polarization to accelerate the wound healing via regulating AMPK/mTOR/NLRP3 inflammasome singling pathway. Am J Transl Res. 2019;11(2):655–68.PubMedPubMedCentral

37.

Gerasymchuk M, Robinson GI, Kovalchuk O, Kovalchuk I. The effects of nutrient signaling regulators in combination with phytocannabinoids on the senescence-associated phenotype in human dermal fibroblasts. Int J Mol Sci. 2022;23(15):8804.CrossRefPubMedPubMedCentral

Titel: Τhe Endless Beauty of Metformin: Does It Also Protect from Skin Aging? A Narrative Review
verfasst von: Evanthia Gouveri
Nikolaos Papanas
Publikationsdatum: 30.01.2023
Verlag: Springer Healthcare
Erschienen in: Advances in Therapy / Ausgabe 4/2023
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-023-02434-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription

Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review

Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies